Apart from delaying the onset of SLE, treatment with one dose of agonistic anti-CD137 antibody in diseased NZB x NZW F1 mice over the age 36 weeks led to marked reduction of serum anti-dsDNA IgG and milder renal inflammation compared to age-matched untreated or isotype-matched antibody-treated mice [34]. This evidence concerns the gene TNFRSF9 and systemic lupus erythematosus.